

1 **Kinetics of *de novo* Bone and Bone Marrow Niche Formation with Hybrid Click Cryogels**

2 Sangmin Lee^{1,2,†}, Kwasi Adu-Berchie^{1,2,†}, Azeem Sanjay Sharda^{3,4,5†}, Tania To^{1,2}, Nikolaos Dimitrakakis²,
3 Alexander Stafford², Katherine Sheehan², Christopher Johnson², Hamza Ijaz², Phoebe Kwon², Mark
4 Cartwright², Sandy Elmehrath², Mary Catherine Skolfield², Des White², Michael Williams², Michael
5 Super², David T. Scadden^{3,4,5*}, and David J. Mooney^{1,2*}

6

7 **Affiliations:**

8 ¹ John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA
9 02138, USA.

10 ² Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02215, USA.

11 ³ Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA.

12 ⁴ Harvard Stem Cell Institute, Cambridge, MA, 02138, USA.

13 ⁵ Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA.

14

15 †These authors contributed equally: Sangmin Lee, Kwasi Adu-Berchie, Azeem Sanjay Sharda

16

17 *Corresponding authors. Email: mooneyd@seas.harvard.edu, david_scadden@harvard.edu

18 Address: Pierce Hall 319, 29 Oxford Street, Cambridge, MA, 02138

19

20

21 **Abstract**

22 Successful hematopoietic stem cell transplantation (HSCT) critically depends on efficient T cell
23 recovery, which is limited by compromised bone marrow niches following irradiation. While
24 various factors influence the regeneration of bone and bone marrow niches, the dynamics of this
25 process remain elusive. Here, we explore the kinetics of *de novo* bone and bone marrow
26 development under varying BMP-2 doses, host immune status, and biological sex, using a cryogel
27 of covalently crosslinked alginate and gelatin releasing BMP-2. Bone formation was monitored
28 by ultrasonography and microcomputed tomography (microCT) analysis, while histological
29 analysis provided insights into the relation between mineralized tissue and bone marrow formation.
30 Bone developed within 2-4 weeks, resulting in cortical bone around the cryogels, and a trabecular

31 bone network with hematopoietic tissue within the cryogels. Higher BMP-2 doses significantly
32 accelerated mineralization kinetics and doubled the resident hematopoietic stem cell population.
33 Notably, immunocompromised status delayed niche development by two weeks and reduced
34 hematopoietic stem cells fourfold. We also found that female mice exhibited enhanced niche
35 formation compared to males under the identical conditions. These findings provide insights into
36 the factors that govern the spatiotemporal regulation of bone and bone marrow niche development
37 and establish this hybrid click cryogel system as a promising platform for improving T cell
38 reconstitution in HSCT patients.

39

40 **Introduction**

41 In the treatment of hematological disorders, allogeneic hematopoietic stem cell transplantation
42 (HSCT) has become an important therapeutic strategy for severe disease including leukemia and
43 sickle cell anemia¹⁻³. However, this procedure is accompanied by significant immunological
44 challenges and clinical complications. Patients undergoing HSCT are placed in a prolonged state
45 of severe immunodeficiency significantly increasing the risk of infections and complications like
46 Graft-versus-Host disease (GVHD)⁴. The core of these complex issues lies in the delayed or
47 impaired T cell recovery following bone marrow stress caused by chemotherapy, radiotherapy and
48 the transplantation process³. T cells are integral to the defense mechanism of the immune system,
49 and the recovery of their function is a critical factor in the success of HSCT. Accelerating the
50 reconstitution of immune function is a crucial challenge of this treatment^{5,6}.

51

52 Biomaterials may be utilized to artificially generate bone marrow-like microenvironments suitable
53 to house hematopoietic cells and generate T cell progenitors^{7,8}. In particular, the engineering of
54 ectopic bone and bone marrow niches using osteoinductive biomaterials has demonstrated
55 potential to facilitate immune system reconstitution⁹⁻¹¹. These strategies encompass various
56 approaches: the use of instructive biomaterials¹²⁻¹⁸, delivery of osteoinductive cytokines or
57 angiogenic factors such as bone morphogenetic protein-2 (BMP-2) or vascular endothelial
58 growth factor (VEGF)^{7,19-24}, and genetic modifications²⁵. We have previously demonstrated a
59 methacrylate-alginate cryogel that creates a bone marrow-like niche capable of guiding
60 hematopoietic stem cells (HSCs) toward the T cell lineage and improving T cell reconstitution²⁶.
61 However, the field has limited understanding regarding factors influencing the rate and extent of
62 de novo bone and bone marrow formation, including BMP-2 dose²⁷, endogenous factors^{28,29}, host
63 immune status³⁰, biological sex³¹⁻³³ and age³⁴.

64
65 Here, we explore the impact of BMP-2 dose, biological sex, and immune competence on ectopic
66 bone formation. To better replicate natural bone composition, alginate-gelatin hybrid cryogels
67 were fabricated for BMP-2 delivery, and the kinetics of bone and bone marrow development were
68 investigated through real-time ultrasonography. Data from ultrasonography, microCT analysis,
69 histological analysis, and flow cytometry was compared and correlated to gain a deeper
70 understanding of the dynamics of bone and bone marrow formation. Our findings indicate that the
71 development of bone and bone marrow with hybrid cryogels is largely influenced by the BMP-2
72 dose. Notably, immunocompromised mice and male mice exhibited delayed and diminished bone
73 and bone marrow-like formation compared to immunocompetent mice and female mice,


74 respectively. Finally, the impact of these biomaterials on post-HSCT immune reconstitution was
75 evaluated.

76

77 **Results**

78 **3.1. Fabrication of hybrid click cryogels.**

79 Scaffolds were intended to mimic the structure of bone³⁵, and enable host progenitors to infiltrate
80 and undergo osteogenesis via the release of BMP-2. (**Fig. 1A**) Scaffolds were fabricated by
81 crosslinking tetrazine-modified alginate with norbornene-modified gelatin in a partially frozen
82 state (cryogelation) (**Fig. 1B**). The click reaction between tetrazine and norbornene led to gelation
83 within several minutes (**Supplementary Fig. 1a**) and resulted in cylindrical cryogels containing
84 highly interconnected pores (**Fig. 1C-E**). These cryogels exhibited consistent mechanical
85 properties (**Supplementary Fig. 1b, c**) and maintained high interconnected porosity and shape
86 recovery properties after injection through a 16-gauge needle (**Supplementary Fig. 2**).



87

88 **Figure 1.** Fabrication and characterization of hybrid click cryogels. (A) Schematic illustrating the
89 concept of hybrid click cryogels for de novo bone formation. (B) Schematic showing the
90 modification of alginate and gelatin with tetrazine and norbornene respectively, and subsequent
91 cryogelation process. (C) Representative optical image of a hybrid click cryogel. (D) High
92 magnification fluorescent image of macroporous hybrid click cryogels. FITC-labeled fluorescent
93 alginate and rhodamine-labeled fluorescent gelatin were used to visualize the polymers in cryogels.
94 (E) High magnification SEM image of hybrid click cryogels.


95

96 3.2. Kinetics of de novo bone formation from BMP-2 loaded Hybrid Click Cryogels.

97 To investigate bone formation with hybrid click cryogels, BMP-2 was loaded into the cryogels
98 using two approaches: incorporating BMP-2 into the polymer mixture before gelation, and adding
99 BMP-2 post-gelation (**Fig. 2A**). BMP-2, which is positively charged at physiological pH, was

100 expected to bind to both the negatively-charged alginate polymer and negatively-charged amino
101 acid residues in gelatin via electrostatic interactions ^{19,36,37}, enabling gradual release.
102 Quantification of BMP-2 release from cryogels (loaded pre-gelation) revealed sustained release
103 over 14 days (**Fig. 2B**). Cryogels containing either 5 ug or 20 ug of BMP-2 were then injected into
104 the subcutaneous tissue of mice, and subsequent mineralization monitored with high-frequency
105 ultrasound sonography (HFUS) (**Fig. 3C**). In ultrasonography images, the cryogels initially
106 appeared grey and hypoechoic relative to the epidermis, while mineralized tissue appeared white
107 and hyperechoic relative to the cryogels. As mineralization progressed and the bone matured, a
108 strong black shadow formed beneath the hyperechoic region. Using these distinct features of bone
109 and cryogels in ultrasonography, we quantified the volumes of gel and mineralization regions over
110 time. Overall, a positive correlation was found between gel volume and mineralization volume.
111 Additionally, the gel volume decreased as mineralization volume increased over time
112 (**Supplementary Fig. 3**). Representative ultrasound images demonstrated strong mineralization of
113 cryogels loaded with 20 ug BMP-2, whereas cryogels with 5 ug BMP-2 exhibited lower
114 mineralization at day 17. By day 31, cryogels with 5 ug BMP-2 demonstrated increased
115 mineralization (**Fig. 2D**). Scoring cryogel mineralization on a 4-point scale (**Supplementary Fig.**
116 **4**) revealed that cryogels with 20 ug BMP-2 scored 3 by day 17, increasing to 4 by day 31, while
117 cryogels with 5 ug BMP-2 scored 2 by day 17, reaching 3 by day 31 (**Fig. 2E, F**). No significant
118 differences in mineralization kinetics between pre- and post-gelation BMP-2 incorporation were
119 found.

120



121

122 **Figure 2.** Kinetics of de novo bone formation with hybrid click cryogels using ultrasonography.
 123 (A) Schematic comparing BMP-2 loading in cryogels, either during or after cryogelation. (B)
 124 BMP-2 release profile from cryogels (BMP-2 loaded during cryogelation). Data represents mean
 125 \pm standard deviation (n=3). (C) In vivo experimental plan for subcutaneous injection of BMP-2
 126 loaded cryogels, followed by ultrasound imaging using high frequency ultrasonography (HFUS).
 127 (D) Representative ultrasonography images demonstrating ectopic mineralization of BMP-2

128 loaded cryogels at day 17 and day 31. Click 20+ represents condition with BMP-2 loaded post-
129 cryogelation. (E) Ectopic mineralization scores for each individual cryogel for each condition at
130 different time points. (F) Mean ectopic mineralization scores for each cryogel condition over time.
131 Data represents mean \pm standard deviation (n=8). An ordinary two-way ANOVA with Tukey's
132 multiple comparison test was used.

133

134 **3.3. Impact of BMP-2 dose on bone and bone marrow formation.**

135 Cryogels were explanted on day 35 to quantify calcified tissue and bone marrow formation, and
136 cellularity. Macroscopically, the explanted cryogels appeared darker and had a harder texture as
137 compared to cryogels at the time of implantation, and cryogels loaded with 20 ug BMP-2 appeared
138 larger than those with 5 ug BMP-2 (**Supplementary Fig. 5**). Qualitatively, microCT analysis
139 revealed newly developed bone covered the entire gel, forming a trabecular-like network, in
140 cryogels with 20 ug BMP-2. In contrast, cryogels loaded with 5 ug BMP-2 exhibited a
141 discontinuous shell of mineralized tissue with large pores (**Fig. 3A**). Quantification confirmed that
142 cryogels with 20 ug BMP-2 had greater mineralization, a higher calcified-to-uncalcified volume
143 ratio and thicker trabeculae compared to those with 5 ug BMP-2. Additionally, pre-incorporated
144 of BMP-2 (20 ug dose) led to higher calcified-to-uncalcified volume ratio and thicker trabeculae
145 than those with post-incorporated BMP-2 (**Fig. 3B, C, Supplementary Fig. 6**). Comparison of
146 total cryogel volumes estimated in situ via ultrasound imaging and after dissection with microCT
147 analysis revealed a linear correlation between the two measurements. Additionally, comparison of
148 bone score based on ultrasound imaging and calcified volume after dissection with microCT
149 analysis revealed a linear correlation between the two measurements (**Supplementary Fig. 7**).

150


151 The distribution of bone and bone marrow in the cryogels was next analyzed through histological
152 staining with H&E and Masson's trichrome. In the 20 ug BMP-2 gels, bone formed predominantly

153 at the cryogel edges, with spicules extending to the interior, while bone marrow hematopoietic
154 niches with high cell densities were present near the gel periphery. Red blood cells (RBCs) were
155 apparent throughout the gel volume. In contrast, the 5 ug BMP-2 gels exhibited a disconnected
156 bony shell with small spicules within the cryogels, alongside marginal hematopoietic niches and
157 minimal RBC infiltration (**Fig. 3D, Supplementary Fig. 8**). The quantities of mineralized tissue
158 and bone marrow were then analyzed from H&E-stained images using a 4-point scale
159 (**Supplementary Fig. 9a, b**). The mineralized tissue scores positively correlated with the presence
160 of bone marrow across all conditions, with higher scores observed for both types of 20 ug BMP-2
161 gels compared to 5 ug BMP-2. Notably, pre-incorporated BMP-2 gels exhibited greater
162 mineralized tissue and bone marrow formation than post-incorporated BMP-2, consistent with
163 microCT findings (**Fig. 3E, Supplementary Fig. 9c, d**).

164

165 The cell populations in the formed bony tissues were next analyzed through flow cytometry. The
166 20 ug BMP-2 gels contained 10 times more infiltrated cells than the 5 ug BMP-2 gels (**Fig. 3F,**
167 **Supplementary Fig. 10a**). Among these, 70% were lineage-negative cells, indicating that the cell
168 populations near the peripheral bone regions likely comprise a hematopoietic niche. Further
169 analysis revealed 0.2% of lineage negative cells were hematopoietic stem and progenitor cells
170 (Lin-Sca1+cKit+). Although the 20 ug BMP-2 gels showed a slightly higher hematopoietic cell
171 population than the 5 ug BMP-2 gels, the increase was not statistically significant (**Fig. 3G, H and**
172 **Supplementary Fig. 10b, c**). Mature T cells, myeloid cells, and B cells were also present in the
173 gels (**Supplementary Fig. 10d**).

174



175

176 **Figure 3.** Characterization of de novo bone and bone marrow formation by cryogels. (A)
 177 Representative macroscopic optical images, 3D reconstruction and representative tissue cross-
 178 sections from microCT analysis of cryogels explanted 35 days post-injection. (B) Percentage of
 179 tissue that was mineralized (C), and calcified-to-uncalcified volume ratio of explanted cryogels.
 180 Data represents mean \pm standard deviation (n=4). An ordinary one-way ANOVA with post hoc
 181 Tukey's multiple comparison test was used; *p < 0.05, **p \leq 0.01. (D) Representative H&E
 182 staining of explanted cryogels imaged at low and high magnification. Scale bars represent 500 μ m
 183 (top row), 100 μ m (middle and bottom row). (E) Correlation between bone score and bone marrow

184 score. Flow analysis quantifying the (F) total number of infiltrated cells, (G) lineage-negative cells,
185 and (H) Lin-Sca-1+cKit+(LKS) cells in explanted cryogels. Data represents mean \pm standard
186 deviation (n=4).

187


188 **3.4. Impact of biological sex and immunocompetency on bone formation**

189 Next, we investigated how biological sex and immunocompetency of mice affected the kinetics of
190 de novo bone formation from BMP-2 loaded cryogels. Cryogels with 5 and 20 ug BMP-2 were
191 injected subcutaneously in male and female mice with lethally irradiation or not. We designated
192 the lethally irradiated mice as having an immunocompromised condition and the intact mice as
193 having an immunocompetent condition. Immunocompromised mice received HSC transplantation
194 in addition to cryogel injection. De novo bone formation was tracked and scored via
195 ultrasonography on days 17 and 33 (**Fig. 4A**). Immunocompetent mice exhibited faster and more
196 extensive mineralization than immunocompromised mice especially in the 5 ug BMP-2 group,
197 while 20 ug BMP-2 group show similar mineralization kinetics. This difference was gradually
198 diminished over time in 5 ug BMP-2 group (**Fig. 4B, C**). In both immunocompromised and
199 immunocompetent groups, male mice showed slower and reduced mineralization compared to
200 female mice at the 5 ug BMP-2 dose. However, as the BMP-2 dose increased, mineralization
201 differences between male and female mice diminished, with no significant sex-based differences
202 observed, regardless of immunocompetency at the 20 ug dose. (**Fig. 4D, E**)

203


204 The cryogels were extracted on day 35 to further assess the amount and quality of de novo bone
205 formation. Consistent with ultrasonography findings, microCT revealed that female mice exhibited
206 relatively greater mineralization than male mice in the 5 ug BMP-2 group, regardless of
207 immunocompetency. In the 20 ug BMP-2 group, no significant differences were observed between

208 male and female mice within the same immunocompetency group, nor between
209 immunocompromised and immunocompetent mice within the same sex group (**Fig. 5A, B,**
210 **Supplementary Fig. 11**). Further analysis scored the quality of bone and bone marrow from
211 histology results. Immunocompetent mice exhibited pronounced cortical bone with spicules (bone
212 score: 4) and had medium to large size region of hematopoiesis, either at the periphery or inside
213 the scaffold (bone marrow score: 3 or 4) in both sexes, while immunocompromised mice,
214 particularly males, showed robust bone formation but had smaller bone marrow niches in the
215 peripheral region (bone marrow score: 2) or no bone marrow (bone marrow score:1) (**Fig. 5C, D**).
216 In the immunocompetent group, both females and males developed substantial bone and bone
217 marrow niches in the 20 ug BMP-2 group. In the immunocompromised group, bone formation was
218 prominent in both sexes, but bone marrow was more prominent in females than males, and within
219 the 20 ug BMP-2 group. (**Fig. 5E, F**) The quantities of lineage negative cells in explanted cryogels
220 mirrored the results seen in bone and bone marrow scores. The immunocompetent group showed
221 a greater number of lineage negative cells compared to the immunocompromised group.
222 Interestingly, while the 20 ug BMP-2 dose resulted in a relatively higher number of cells compared
223 to 5 ug BMP-2 in the immunocompromised group, similar numbers of lineage negative cells were
224 observed for both 5 ug and 20 ug BMP-2 treatments in the immunocompetent group, regardless of
225 sex (**Fig. 5G, H**). The number of LKS (Lin-cKit+Sca1+) cells measured on day 35 after irradiation
226 was BMP-2 dose dependent in the immunocompromised group, but not in the immunocompetent
227 group (**Supplementary Fig. 12, 13**).



228

229 **Figure 4.** Effect of biological sex and immunocompetency on de novo bone formation kinetics.
 230 (A) In vivo experimental plan for subcutaneous injection of BMP-2 loaded cryogels in either
 231 female or male, immunocompromised or immunocompetent mice, followed by ultrasound imaging
 232 using HFUS. Comparison of de novo bone formation kinetics between immunocompromised and
 233 immunocompetent conditions in (B) female mice and (C) male mice. Comparison of de novo bone
 234 formation kinetics between female and male mice in (D) immunocompromised and (E)
 235 immunocompetent condition. Data represents mean \pm standard deviation ($n=4$). An ordinary one-
 236 way ANOVA with post hoc Tuckey's multiple comparison test was used; * $P < 0.05$.



238 **Figure 5.** Characterization of de novo bone formation amount and quality as a function of sex and
239 immunocompetency. (A) Representative microCT images of explanted cryogels (day 35). (B)
240 Percentage of mineralization in explanted cryogels. (C) Histological analysis-based bone and bone
241 marrow scores in (C) female mice and (D) male mice under different immune statuses:
242 immunocompromised or immunocompetent. (E) Histological analysis-based bone and bone
243 marrow scores in (E) immunocompetent and (F) immunocompromised conditions under different
244 sex. Data represents mean \pm standard deviation (n=4). Flow analysis quantifying the population of
245 lineage-negative cells in (G) immunocompetent and (H) immunocompromised conditions. Data
246 represents mean \pm standard deviation for n=4 cryogels.

247

248 **3.5. T cell reconstitution from ectopic bone**


249 We next examined the impact of cryogel-mediated bone formation on the kinetics and magnitude
250 of T cell reconstitution following lethal irradiation and hematopoietic stem cell (HSC)
251 transplantation. Lethally irradiated, HSC-transplanted mice were injected with either blank click
252 hybrid cryogels or click hybrid cryogels loaded with 20 ug BMP-2 (**Fig. 6A**). As a control, we
253 examined the peripheral blood analysis of mice without cryogels, with or without lethal-irradiation,
254 and it showed the significantly decreased T cell numbers in immunocompromised conditions
255 compared to immunocompetent conditions (**Supplementary Fig. 14**). Sequential blood analysis
256 at various time points after cryogel injection revealed that mice receiving BMP-2 loaded cryogels
257 showed a trend for faster reconstitution kinetics for white blood cells, lymphocytes, and donor T
258 cells compared to those receiving blank cryogels in female mice (**Fig. 6B, C, Supplementary Fig.**
259 **15**). Also, females showed significantly larger donor T cell populations after 6 weeks of
260 transplantation compared to males, while there was no significant difference in B cell populations
261 over time (**Supplementary Fig. 16a**). After 84 days, the cryogels were explanted to examine the
262 cellular populations within the BMP-2 loaded cryogels and compare to those in blank cryogels.
263 The number of infiltrated cells in BMP-2 loaded cryogels was over 100 times higher than in blank
264 cryogels. Significantly higher numbers of donor T cells, lineage-negative cells, and LKS cell

265 populations were found residing in the BMP-2-loaded cryogels compared to the blank cryogels.
266 This suggest that the HSCs circulating in the blood proliferated and differentiated within the BMP-
267 2-loaded cryogels (**Fig. 6D-G**). Moreover, females showed significantly larger populations of
268 immune cells including T cells, B cells, and neutrophils, as well as hematopoietic cells including
269 lineage-negative cells and LKS cells, in the BMP-2-loaded cryogels compared to males
270 (**Supplementary Fig. 16b**). This trend of females outperforming males in terms of immune cell
271 and hematopoietic cell population development in cryogels was only noted at this later time point,
272 as we observed no significant difference between females and males at day 35 (**Supplementary**
273 **Fig. 12b, c**). Histology results showed distinct bone marrow-like hematopoietic tissue residing
274 near the ectopic bone in BMP-2 loaded cryogels, whereas cell infiltration in blank cryogels was
275 minimal (**Fig. 6H, I**). In the bone marrow-like niches, the majority of cells expressed CD45,
276 indicating hematopoietic lineage, while fewer cells infiltrating blank cryogels expressed CD45.
277 Notably, some cells within the bone marrow-like niches also expressed Notch intracellular
278 domains (NICD) and DLL4 (**Fig. 6J, Supplementary Fig. 17**), signaling pathways that drive the
279 differentiation of HSCs into T cell-lineage populations.

280

281

282



284 **Figure 6.** T cell reconstitution from ectopic bone. (A) In vivo experimental plan for T cell
285 reconstitution through lethal irradiation and HSCs transplantation, followed by subcutaneous
286 injection of BMP-2 loaded cryogels. Quantification of circulating immune cell population: (B)
287 lymphocytes and (C) donor T cells over time. Data represents mean \pm standard deviation (n=10).
288 An ordinary two-way ANOVA with Šídák's multiple comparison test was used; * $p \leq 0.05$, ** $p \leq$
289 0.01 , **** $p \leq 0.0001$. (D-G) Cell counts in explanted cryogels: (D) infiltrated live cells, (E) donor
290 T cells, (F) lineage-negative cells, and (G) LKS cell population. Data represents mean \pm standard
291 deviation (n=10). An unpaired t-tests using Welch's correction was used; ** $p \leq 0.01$, **** $p \leq$
292 0.0001 . (H-I) Representative H&E images of blank cryogels and BMP-2 loaded click hybrid
293 cryogels at (H) low and (I) high magnification. Yellow arrows depict the hematopoietic tissue
294 region. Scale bars represent 500 μm (H) and 100 μm (I). (J) Representative immunohistochemistry
295 images of explanted blank cryogels and BMP-2 loaded click hybrid cryogels, showing staining for
296 different cell populations: immune cells in white, Notch intracellular domains (NICD; Notch-
297 activated cells) in pink, DLL4-expressing cells in green. (Nucleus: blue; CD45+: white; NICD:
298 pink; DLL4: green) Scale bars represent 50 μm .

299

300 Discussion

301 This study explored the kinetics of de novo bone and bone marrow development under varying
302 BMP-2 doses, host immune status, and biological sex using BMP-2 loaded hybrid click cryogels.
303 Multimodal analysis, including ultrasonography, microCT, histology, and flow cytometry, revealed
304 a linear correlation between bone and bone marrow-like niche development in biomaterials-based
305 platform. These findings revealed that higher BMP-2 doses, immunocompetency, and female mice
306 resulted in significantly faster mineralization and hematopoiesis with a larger population of
307 hematopoietic stem/progenitor cells compared to lower BMP-2 doses, immunocompromised
308 conditions, and male mice. Finally, BMP-2 loaded hybrid click cryogels expanded hematopoietic
309 stem/progenitor cells and accelerated the expansion of donor T cells compared to blank cryogels.

310 The biomaterial strategy developed here addresses limitations of the traditional
311 biomaterial-based platforms used for ectopic mineralization - disk-shaped implantable scaffolds
312 or injectable in situ forming gels. While implantable scaffolds provide reliable mechanical support,

313 they necessitate invasive surgeries with associated inflammation¹⁰. Injectable in situ forming gels
314 offer a minimally invasive alternative and can be effective when an injection pocket is available.
315 However, these gels often lack mechanical stability due to a limited window for gelation time and
316 concentration constraints necessary for injectability. The injectable, rod-shaped hybrid click
317 cryogels described in this study address these limitations, as these pre-formed scaffolds utilize
318 click chemistry to provide precise control over mechanical properties while maintaining
319 injectability through standard syringes, enabling minimally invasive delivery.

320 The hybrid click cryogels we developed serve as a platform for ectopic bone and bone
321 marrow-like niche development, with their macroporous structure providing high surface area for
322 effective BMP-2 loading and controlled release. We loaded BMP-2 into hybrid click cryogels
323 through two different approaches: during cryo-gelation or after cryo-gelation. Our observations
324 suggest that the cryo-gelation process facilitates more effective binding between BMP-2 and
325 alginate. This enhanced binding may be attributed to the space confinement of BMP-2 in the
326 polymer-rich phase during cryo-gelation, which appears to accelerate binding compared to the
327 diffusion-derived binding that occurs when loading BMP-2 after cryo-gelation. Moreover, we
328 observed slightly better mineralization and hematopoietic tissue formation when BMP-2 was
329 loaded during cryo-gelation, indicating that this method may be preferable for tissue engineering
330 outcomes. Our results demonstrate that BMP-2 loaded hybrid click cryogels successfully
331 recapitulate key features of native bone tissue, including both cortical and trabecular bone structure,
332 along with hematopoietic tissue resembling the bone marrow niche, in a dosage-dependent manner.
333 Higher BMP-2 doses not only accelerated the mineralization process but also resulted in more
334 extensive hematopoietic tissue formation, with a twofold increase in the hematopoietic stem cell
335 population compared to lower doses. These observations align with previous studies that have

336 established BMP-2 as an osteoinductive cytokine that promotes mineralization³⁸⁻⁴⁰. Here, notably,
337 BMP-2 maintains its biological activity despite exposure to partial freezing during the cryo-
338 gelation process.

339 The multimodal analysis of de novo bone and bone marrow-like niche formation in hybrid
340 click cryogels revealed a linear correlation between mineralized tissue and bone marrow
341 development. While microCT analysis has been traditionally used to analyze mineralization
342 quantitatively, it lacks the ability to quantify hematopoietic tissue development⁴¹⁻⁴³. To address this
343 limitation, we introduced a novel histology data-based scoring metric that can assess the extent of
344 both bone formation and bone marrow development within the same sample. Validating our
345 approach, we found that the bone scores correlated strongly with microCT quantification data
346 (**Supplementary Fig. 7c**), while bone marrow scores showed consistent trends with flow
347 cytometry analyses of hematopoietic cell population. Further, the kinetics of mineralization
348 significantly affected bone and bone marrow development, as demonstrated through in-situ
349 ultrasonographic monitoring and histology analysis of hybrid click cryogels. Notably, slower
350 mineralization rates resulted in reduced hematopoietic tissue formation compared to faster
351 mineralization processes, despite both conditions achieving similar extent of mineralization. This
352 observation suggests that the rate of mineralization, not just final mineral content, plays a crucial
353 role in determining the development of hematopoietic tissue.

354 Our investigation into de novo bone and bone marrow development reveals critical
355 differences in these processes between immunocompromised and immunocompetent animals. In
356 immunocompromised mice, induced by irradiation and hematopoietic stem cell transplantation,
357 we observed delayed mineralization and reduced hematopoietic tissue development compared to
358 immunocompetent mice, consistent with previous studies demonstrating compromised bone

359 quality in the absence of a functional host immune system, especially mature T and B cells ^{10,44}
360 **(Supplementary Fig. 14)**. While this impairment was evident across BMP-2 doses, higher doses
361 partially mitigated these effects, suggesting a dose-dependent compensatory mechanism on
362 immunodeficiency. To understand the underlying mechanisms, we examined cellular populations
363 and found significantly decreased T and B cell numbers in immunocompromised conditions
364 **(Supplementary Fig. 13, 14)**. This depletion of immune cells, along with the reduction in stromal
365 cells and vascularization due to irradiation, likely directly impacts the BMP-2-induced ectopic
366 mineralization process. Typically, the process of de novo bone formation begins with stromal cell
367 recruitment followed by osteogenesis ^{10,45,46}. However, our results, consistent with prior research
368 ⁴⁷⁻⁵⁰, suggests that irradiated stromal cells were less effective in activating and differentiating into
369 osteoblasts during BMP-2-induced ectopic mineralization compared to intact stromal cells. The
370 effects of the immunocompromised condition extended beyond bone formation to the
371 hematopoietic niche. We observed significant decreases in lineage-negative cells and
372 hematopoietic stem cells (Lin-Sca1+c-kit+) within mineralized cryogels, particularly at lower
373 BMP-2 doses **(Supplementary Fig. 13)**.

374 Biological sex was found to play an important role in de novo bone and bone marrow
375 development under immunocompromised conditions. Our findings indicate that male mice
376 exhibited slower mineralization kinetics and developed smaller hematopoietic tissues compared to
377 females with the same BMP-2 dosage. These results challenge previous studies that have shown
378 females are generally more compromised in bone development due to their hormones and higher
379 osteoclast resorptive activity compared to males ⁵¹⁻⁵⁴; however, it is important to note that most of
380 the previous studies were conducted under homeostatic conditions. In our study, we observed that
381 this sexual effect becomes less pronounced in immunocompetent animals, suggesting that the

382 inflammatory state plays a role in modulating sex-based differences in bone development. We
383 hypothesize that sex differences in immune response between females and males contribute to
384 difference in bone formation, at least in part. This hypothesis is supported by our observation of
385 higher neutrophil levels in females under immunocompromised conditions (**Supplementary Fig.**
386 **12**), along with previous studies showing that females generally have stronger immune responses
387 than males⁵⁵⁻⁵⁷, which may explain the enhanced bone development we observed in females.
388 Furthermore, we find superior T cell reconstitution in females, consistent with the findings on bone
389 development.

390 In conclusion, these findings demonstrate the efficacy of injectable, rod-shaped hybrid
391 click cryogels as a versatile platform for ectopic bone and bone marrow-like niche formation. This
392 approach overcomes certain limitations associated with previous biomaterial-based platforms. The
393 BMP-2 loaded cryogels promoted formation of tissues with features of native bone in a dose-
394 dependent manner. Our findings highlight the critical role of mineralization kinetics, host immune
395 system, and biological sex in de novo bone and bone marrow development within the context of
396 hybrid click cryogels. These results not only advance our understanding of ectopic bone formation
397 but also suggest potential therapeutic applications, particularly in enhancing T cell reconstitution
398 following HSCT.

399

400 **Methods**

401 **Chemical modification of Alginate tetrazine and Gelatin norbornene**

402 Pronova ultrapure MVG sodium alginate (CAS: 9005-38-3, NovaMatrix, Cat# 4200101) was
403 modified with 3-(p-benzylamino)-1,2,4,5-tetrazine (Tz) using carbodiimide chemistry. Briefly,

404 alginate was first dissolved in 0.1 M 2-(N-morpholino) ethanesulfonic acid (MES), 0.3 M NaCl,
405 pH 6.5 at 10 mg/ml. Next, 3.7 g of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
406 hydrochloride (EDC) (ThermoFisher #22980) and 2.2 g of N-hydroxysuccinimide (NHS)
407 (ThermoFisher #24500) were added per gram of alginate. 0.2 g of tetrazine was then added to the
408 dissolved alginate under constant stirring and allowed to react overnight at room temperature. The
409 tetrazine-modified alginate was subsequently purified first by centrifugation at 11,000xg for 15
410 minutes at room temperature, followed by tangential flow filtration (KrosFlow KR2i; Spectrum
411 Labs) against a 150 to 0 mM decreasing NaCl gradient using a 3kDa MWCO membrane (Repligen,
412 Cat# S02-E003-05-N), and then by treatment with 1 g activated charcoal. This was followed by
413 filtration through a 0.22- μ m filter and subsequent lyophilization.

414 Fish Gelatin from cold water fish skin (Sigma Cat #G7041) was modified with 5-Norbornene-2-
415 methylamine (Nb) using carbodiimide chemistry as follows. Briefly, 1g gelatin was dissolved at a
416 final concentration of 5mg/ml in 0.1M MES, 0.3M NaCl buffer, pH 6.5 on a hotplate heated to
417 37°C. Next, 0.38g of EDC and 0.115g of NHS were added per gram of gelatin. 123ul of Nb was
418 then per gram of gelatin under constant stirring and reacted at 37°C overnight. The solution was
419 then dialyzed against decreasing NaCl gradient (150mM to 0mM) for 3 d and lyophilized.

420

421 **Preparation of Hybrid Click Cryogels**

422 To fabricate 2 % wt/vol alginate–gelatin hybrid cryogels comprising 45% alginate and 55% gelatin,
423 lyophilized Gelatin Norbornene (Gel-Nb) was first dissolved to 10 mg/ml in milliQ water and
424 cooled to 4°C. Alginate Tetrazine (Alg-Tz) was freshly dissolved to 2% wt/vol in milliQ water and
425 also cooled to 4°C. Dissolved Gel-Nb and Alg-Tz were mixed, yielding final concentration of 1.1

426 mg/ml and 0.9 mg/ml for gelatin and alginate, respectively. The cryogel mixture was immediately
427 pipetted into pre-chilled 2 mm diameter Tygon tubing (VWR #89404-3018) at 100 ul cryogel
428 mixture per 2 cm tubing, and placed in a -20°C freezer overnight for cryo-polymerization. After
429 cryogelation, the cryogels were thawed at room temperature and ejected by gently flushing the
430 tygon tubing with media (DMEM, high glucose, Glutamax; Gibco, #10566-016).

431 Recombinant Human/Mouse/Rat BMP-2 (R&D systems #355-BM/CF) was incorporated
432 into cryogels by either adding them to the gel mixture and underwent cryogelation as described
433 above or adding them after cryogelation by submerging the hybrid click cryogels into a
434 concentrated BMP-2 solution for 3 hours at 4°C.

435 The BMP-2 release from the hybrid click cryogels was measured using enzyme-linked
436 immunosorbent assay (ELISA; R&D systems, DY355). The BMP-2 loaded hybrid click cryogels
437 were incubated in media (DMEM, high glucose, GlutaMAX + 10% FBS + 1% pen/strep) at 37 °C.
438 The supernatants were collected at each timepoint and replaced with fresh media. Collected
439 supernatants were stored at -80°C until the ELISA was performed.

440

441 **Characterization of Hybrid Click Cryogels**

442 **Scanning Electron Microscopy (SEM)**

443 Cryogels were first fragmented cross-sectionally to expose the inner surface area. Fragmented gels
444 were serially dehydrated by submersion into increasing concentrations of ethanol from 50% to
445 100%. The samples were further dried using liquid CO₂ in the Tousimis 931 GL critical point dryer.
446 Dried cryogels were mounted onto carbon tape on sample chucks. 10 nm of platinum-palladium
447 was deposited on the sample surface using the EMS 150T ES Sputter/Carbon Coater. Samples

448 were imaged with the FESEM (Zeiss Gemini 260 field emission scanning electron microscope) at
449 3 kV with 7 mm working distance and were taken using the secondary emission (SE2) detector.

450

451 **Mechanical properties**

452 Shear rheological analysis was performed on the gels as follows. Lyophilized alginate tetrazine
453 and gelatin norbornene polymers were first dissolved in milliQ water, cooled to 4C and combined
454 in a pre-cooled Eppendorf tube, resulting in 1.1 mg/ml and 0.9 mg/ml final concentrations of
455 gelatin and alginate respectively. 700ul of the gel solution was immediately cast onto a pre-cooled
456 Peltier plate of a CMT rheometer (AR-G2, TA Instrument). A 40mm cone geometry was then used
457 to perform oscillatory time sweep test at 25°C for 2 hours at a 1% strain and 1Hz frequency.

458 Compressive elastic modulus analysis was performed on the pre-formed cryogel. Uniaxial
459 compression tests were conducted using a Bose machine to determine the elastic modulus of the
460 hybrid click cryogels. The cryogels were placed on top of a holder and wicked to remove excess
461 water to prevent slippage during the testing. The cryogels were compressed at a rate of 0.1 mm/min,
462 and the elastic modulus was calculated as the slope of the stress-strain curve between 0 and 15%
463 strain.

464

465 **Estimation of cryogel interconnected porosity and shape recovery**

466 Cryogel interconnected porosity and shape recovery were estimated as previously described ⁵⁸.
467 Briefly, interconnected porosity was estimated by first weighing intact cryogels (M_{hydrated}) and then
468 wicking

469 cryogels with a kimwipe for 15 s to remove the excess buffer from cryogel pores (M_{wicked}).

470 Interconnected porosity was quantified as follows:

471
$$\frac{M_{hydrated} - M_{wicked}}{M_{hydrated}}$$

472 Equation (1): Estimation of interconnected porosity

473 Cryogel shape recovery was estimated by first weighing intact cryogels ($M_{hydrated}$) and
474 wicking as described above. Wicked cryogels were then rehydrated in DPBS and weighed
475 ($M_{rehydrated}$). Shape recovery was quantified as follows:

476
$$\frac{M_{rehydrated}}{M_{hydrated}}$$

477 Equation (2): Estimation of cryogel shape recovery

478

479 **Animal studies**

480 All animal work was approved by the Harvard Institutional Animal Care and Use Committee
481 (IACUC) and followed the National Institutes of Health guidelines and relevant ethical regulations.
482 C57BL/6 (B6, H-2b), C57BL/6 (CD45.1+) and CByJ.B6-Tg(UBC-GFP)30Scha/J (GFP) (Jackson
483 Laboratories) were females or males and between 6 and 8 weeks old at the start of the experiments.
484 All mice in each experiment were age matched and no randomization was performed.

485

486 **In vivo ectopic bone and bone marrow development study.** To investigate ectopic bone and
487 bone marrow development in vivo, BMP-2-loaded hybrid click cryogels were subcutaneously

488 injected into the flanks of female and male C57BL6/J (B6) and C57BL/6 (CD45.1+) mice (Jackson
489 Laboratories) aged between 6 and 8 weeks. Mice were anesthetized when they received
490 subcutaneous injections of two hybrid click cryogels, one in each flank (right and left), which were
491 suspended in saline solution and administered through a 16-gauge needle.

492

493 **In vivo ectopic bone and bone marrow at immunocompromised study.** To recapitulate the allo-
494 HSCT procedures and create immunocompromised conditions, lineage-depleted bone marrow
495 cells were isolated from C57BL/6 (CD45.1+) mice. All total-body irradiation procedures were
496 performed using a cesium-137 gamma-radiation source with a single dose of 1,000 cGy on
497 C57BL/6 (B6) mice. Subsequently, 5×10^5 lineage-depleted GFP+ bone marrow cells were
498 transplanted via retro-orbital injection, and BMP-2-loaded hybrid click cryogels were
499 subcutaneously injected. *T cell reconstitution study*: all cohorts of mice were serially bled: bi-
500 monthly, starting 4 weeks post-transplant. White blood cells, lymphocytes, donor T cells, B cell
501 were quantified by CBC (complete blood count) analysis using an Abaxis VetScan HM5.

502 **Ultrasound imaging and analysis**

503 For ultrasound imaging, mice were anaesthetized and placed on a heating pad with their limbs
504 fixed to prevent movement. Subcutaneously-injected hybrid click cryogels were analyzed using a
505 high-frequency ultrasound device (Vevolab 3100, FUJIFILM VisualSonics) and imaged using a
506 Vevo 3100 scanner with a 50 MHz transducer (MX700) and a 3D motor (VisualSonics; axial
507 resolution, 30 μm ; lateral resolution, 140 μm) to visualize cryogels. The cryogel injection site was
508 shaved and hair was removed to avoid unnecessary scattering. The scanner was placed directly
509 above the injection site. Ultrasound images were acquired every 0.2 mm in the axial plane

510 throughout the cryogels. After imaging, animals were allowed to recover to their normal behavior.
511 3D volume reconstruction of the cryogels including ectopic mineralization was performed using
512 the multi-slice method in Vevolab software (Vevolab 5.7.1). The volume of cryogels and ectopic
513 mineralization was created by segmenting a series of contours from 2D slices of the ultrasound
514 images and rendering them into a 3D image. The ectopic mineralization score was performed by
515 manual observation based on the mineralization area within the cryogels.

516

517 **Micro-Computed Tomography (microCT) acquisition and analysis**

518 To quantify the calcified volume, we conducted microCT analysis through the Preclinical Imaging
519 and Testing Facility at MIT. Mineralized cryogels were extracted from the flank of mice
520 subcutaneously injected with BMP-2-loaded or blank cryogels and submerged in 4%
521 paraformaldehyde (PFA) for fixation. After fixation, the cryogels were transferred into 70%
522 ethanol for microCT analysis. **MicroCT acquisition.** MicroCT imaging was performed using a
523 Skyscan 1276 (Bruker Biospin Corp, Billerica, MA) with Skyscan acquisition software (version
524 1.8) and reconstructed using NRecon (version 1.7.4.2). Ex vivo samples were imaged in air within
525 a sealed container containing ethanol-saturated sponges to minimize evaporation and prevent
526 shrinkage of the soft phase (cellular content and unoccupied polymer), which would otherwise
527 desiccate during scanning. Acquisition parameters were as follows: x-ray source at 55 kVp and
528 200 μ A, 0.25 mm aluminum filter, 680 projections with a 0.3° angular step size, 315 ms exposure
529 time, and a 2×2 detector binning mode, yielding an isotropic voxel size of 10.0 μ m. **MicroCT**
530 **analysis.** Bone and soft phase volumes were quantified from grayscale 3D microCT
531 reconstructions. Intensity thresholds were manually selected based on prior knowledge of the
532 material composition to differentiate bone from the soft phase. The upper threshold defined bone,

533 while a lower threshold identified the soft phase. Both threshold values were applied to all scans.
534 Automated methods, such as Otsu's thresholding, did not provide biologically meaningful
535 segmentation. Volumes were determined by summing the number of voxels assigned to each phase.
536 Image processing and analysis were conducted using ImageJ 1.54f. The volume of cryogels (mm^3)
537 and the volume of calcified regions (mm^3), thickness of trabecular (Tb.Th, cm), and bone mineral
538 density (BMD, g/HACC) were measured from the microCT analysis. The percentage of
539 mineralization was calculated as follows: $(V_{\text{calcified}} / V_{\text{total volume}}) * 100$. The 3D rendering of cross-
540 sectioned tomography imaging was created by segmenting a series of contours from 2D slices of
541 microCT images.

542

543 **Histology and immunofluorescence analysis**

544 For the histological analysis, extracted cryogels were fixed in 4% PFA and transferred into 70%
545 ethanol for staining. PFA-fixed cryogels were partially decalcified and embedded in paraffin wax.
546 Sections (5 μm) of the samples were stained with hematoxylin and eosin (H&E) or Masson's
547 Trichrome. The sections were imaged with a Nikon E800 or ZEISS Axio Scan.Z1 Slide Scanner
548 in bright-field mode.

549 Immunohistochemistry was performed in paraffin sections. Paraffin sections were
550 deparaffinized and then processed with antigen retrieval treatments using Dako Target Retrieval
551 Solution (Agilent), prior to standard immunostaining procedures. The sectioned samples were
552 stained using standard immunohistochemistry protocols. The samples were permeabilized with
553 phosphate buffered saline (PBS) containing 0.1% Tween 20 or Triton X (PBST), and blocked with
554 PBST containing 10% bovine serum albumin and 10% goat serum. The following antibodies and

555 reagents were used for immunohistochemistry: CD45 (ab10558, Abcam), NICD (ab52301,
556 Abcam), DLL4 (AF1389, R&D systems), Hoechst 33258 (H21491, Invitrogen), and Prolong Gold
557 antifade reagent (Invitrogen). The sections were imaged with a ZEISS Axio Scan.Z1 Slide Scanner
558 in bright-field mode. ImageJ was used for post-image analysis

559

560 **Flow cytometry analysis**

561 Cells harvest was performed on long bones (femurs) and mature cryogels using Digestion buffer
562 comprised of RPMI1640, 10% FBS, 1% Pen/Strep, 0.2mg/ml Alginate Lyase (Sigma #A1603) and
563 Collagenase Type IV 250U/ml (Gibco # 17104019). Bone/Cryogels were chopped into pieces
564 <1mm using a pair of scissors in presence of 2ml Digestion buffer in a 10mm petri dish. Contents
565 are transferred into a 15ml conical tube. Petri dish is washed twice with 2ml Digestion buffer to
566 transfer any remaining material/cells. Contents in the 15ml conical tube (6ml) are incubated in a
567 shaker at 37°C, 200 RPM for 1 hour. The contents of 15ml tube are transferred to a 50ml tube
568 through a 70uM cell strainer. 10ml of 1X PBS are added to the 15ml tube to rinse any stuck cells,
569 transferred back into 50ml tube through 70uM cell strainer. Contents are spun down (500g, 4°C,
570 5mins). Supernatant is discarded. Samples are incubated in 500ul of ACK lysis on ice to get rid of
571 RBCs. 10ml of FACS buffer (1x PBS + 2%FBS + 1% Pen/Strep) is added for wash, spun down
572 (500g, 4°C, 5mins) and supernatant is discarded. Cells are transferred into a 1ml Eppendorf tube,
573 FACS buffer added to make volume up to 1ml. Samples are now ready for Flow cytometric
574 analyses.

575 Anti-mouse antibodies to CD45 (104), CD4 (GK1.5), CD8 α (53-6.7), CD3 ϵ (17A2), B220 (RA3-
576 6B2), CD11b (M1/70), Lineage cocktail (17A2; RB6-8C5; RA3-6B2; Ter-119; M1/70), CD117

577 (2B8), Sca-1 (D7) CD127 (A7R34), CD150 (TC15-12F12.2), CD48 (HM48-1) and Live/Dead
578 blue stain kit (Invitrogen # L34962), and the corresponding isotype control antibodies were
579 purchased from BioLegend. All cells were gated based on forward and side scatter characteristics
580 to limit debris, including dead cells. Antibodies were diluted according to the manufacturer's
581 suggestions. Cells were gated based on fluorescence-minus-one controls, and the frequencies of
582 cells staining positive for each marker were recorded. To quantify T, B and myeloid cells, blood
583 samples underwent lysis of red blood cells and were stained with anti-CD45, anti-B220, anti-CD3,
584 anti-CD4, anti-CD8 and anti-CD11b antibodies; absolute numbers of T, B and myeloid cells were
585 calculated using flow cytometry frequencies. Flow Cytometry data was analyzed using FlowJo.

586

587 **Statistical Analysis**

588 All statistical analyses were performed using Prism Graphpad software version 10.4.1. Statistical
589 tests included Student's t-test with Welch's correction for comparisons between two groups, and
590 two-tail one-way ANOVA with post hoc Tukey's multiple comparison test for group comparisons.
591 Two-way ANOVA with repeated measures was used for circulating immune cell quantification. A
592 p-value < 0.05 was considered statistically significant. Data are presented as means, and error bars
593 represent the standard deviation unless otherwise noted.

594

595 **Data availability**

596 The data that support the findings of this study are available from the corresponding authors upon
597 reasonable request.

598

599 References

- 600 1 Du, J., Yu, D., Han, X., Zhu, L. & Huang, Z. Comparison of Allogeneic Stem Cell
601 Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-
602 Cell Lymphoma: A Systematic Review and Meta-analysis. *JAMA Netw Open* **4**, e219807
603 (2021). <https://doi.org/10.1001/jamanetworkopen.2021.9807>
- 604 2 Jenq, R. R. & van den Brink, M. R. Allogeneic haematopoietic stem cell transplantation:
605 individualized stem cell and immune therapy of cancer. *Nat Rev Cancer* **10**, 213-221
606 (2010). <https://doi.org/10.1038/nrc2804>
- 607 3 Velardi, E., Tsai, J. J. & van den Brink, M. R. M. T cell regeneration after immunological
608 injury. *Nat Rev Immunol* **21**, 277-291 (2021). [https://doi.org/10.1038/s41577-020-00457-](https://doi.org/10.1038/s41577-020-00457-z)
609 [z](https://doi.org/10.1038/s41577-020-00457-z)
- 610 4 McDonald-Hyman, C., Turka, L. A. & Blazar, B. R. Advances and challenges in
611 immunotherapy for solid organ and hematopoietic stem cell transplantation. *Sci Transl*
612 *Med* **7**, 280rv282 (2015). <https://doi.org/10.1126/scitranslmed.aaa6853>
- 613 5 Hasan, T. *et al.* Homing and Engraftment of Hematopoietic Stem Cells Following
614 Transplantation: A Pre-Clinical Perspective. *Curr Oncol* **31**, 603-616 (2024).
615 <https://doi.org/10.3390/currencol31020044>
- 616 6 Yanir, A., Schulz, A., Lawitschka, A., Nierkens, S. & Eyrich, M. Immune Reconstitution
617 After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to
618 Targeted Interventions. *Front Pediatr* **9**, 786017 (2021).
619 <https://doi.org/10.3389/fped.2021.786017>
- 620 7 Torisawa, Y. S. *et al.* Bone marrow-on-a-chip replicates hematopoietic niche physiology
621 in vitro. *Nat Methods* **11**, 663-669 (2014). <https://doi.org/10.1038/nmeth.2938>
- 622 8 Nelson, M. R. & Roy, K. Bone-marrow mimicking biomaterial niches for studying
623 hematopoietic stem and progenitor cells. *J Mater Chem B* **4**, 3490-3503 (2016).
624 <https://doi.org/10.1039/c5tb02644j>
- 625 9 Chen, X. *et al.* Correlations between macrophage polarization and osteoinduction of
626 porous calcium phosphate ceramics. *Acta Biomater* **103**, 318-332 (2020).
627 <https://doi.org/10.1016/j.actbio.2019.12.019>
- 628 10 Zhao, Z. *et al.* Minimally invasive implantation and decreased inflammation reduce
629 osteoinduction of biomaterial. *Theranostics* **10**, 3533-3545 (2020).
630 <https://doi.org/10.7150/thno.39507>
- 631 11 Lee, J., Byun, H., Madhurakkat Perikamana, S. K., Lee, S. & Shin, H. Current Advances
632 in Immunomodulatory Biomaterials for Bone Regeneration. *Adv Healthc Mater* **8**,
633 e1801106 (2019). <https://doi.org/10.1002/adhm.201801106>
- 634 12 Chen, F. *et al.* Enhanced ectopic bone formation by strontium-substituted calcium
635 phosphate ceramics through regulation of osteoclastogenesis and osteoblastogenesis.
636 *Biomater Sci* **10**, 5925-5937 (2022). <https://doi.org/10.1039/d2bm00348a>
- 637 13 Mao, Z. *et al.* Mechanically robust and personalized silk fibroin-magnesium composite
638 scaffolds with water-responsive shape-memory for irregular bone regeneration. *Nat*
639 *Commun* **15**, 4160 (2024). <https://doi.org/10.1038/s41467-024-48417-8>
- 640 14 Karageorgiou, V. & Kaplan, D. Porosity of 3D biomaterial scaffolds and osteogenesis.
641 *Biomaterials* **26**, 5474-5491 (2005). <https://doi.org/10.1016/j.biomaterials.2005.02.002>

- 642 15 Wang, P. *et al.* Bone tissue engineering via nanostructured calcium phosphate
643 biomaterials and stem cells. *Bone Res* **2**, 14017 (2014).
644 <https://doi.org/10.1038/boneres.2014.17>
- 645 16 Sutha, K. *et al.* Osteogenic embryoid body-derived material induces bone formation in
646 vivo. *Sci Rep* **5**, 9960 (2015). <https://doi.org/10.1038/srep09960>
- 647 17 Schwartz, Z. *et al.* Differential effects of bone graft substitutes on regeneration of bone
648 marrow. *Clin Oral Implants Res* **19**, 1233-1245 (2008). <https://doi.org/10.1111/j.1600-0501.2008.01582.x>
- 649 18 Calabrese, G. *et al.* Bone augmentation after ectopic implantation of a cell-free collagen-
650 hydroxyapatite scaffold in the mouse. *Sci Rep* **6**, 36399 (2016).
651 <https://doi.org/10.1038/srep36399>
- 652 19 Hettiaratchi, M. H. *et al.* Heparin-mediated delivery of bone morphogenetic protein-2
653 improves spatial localization of bone regeneration. *Sci Adv* **6**, eaay1240 (2020).
654 <https://doi.org/10.1126/sciadv.aay1240>
- 655 20 Wise, J. K., Sumner, D. R. & Viridi, A. S. Modulation of stromal cell-derived factor-
656 1/CXC chemokine receptor 4 axis enhances rhBMP-2-induced ectopic bone formation.
657 *Tissue Eng Part A* **18**, 860-869 (2012). <https://doi.org/10.1089/ten.TEA.2011.0187>
- 658 21 Fahmy-Garcia, S. *et al.* Novel In Situ Gelling Hydrogels Loaded with Recombinant
659 Collagen Peptide Microspheres as a Slow-Release System Induce Ectopic Bone
660 Formation. *Adv Healthc Mater* **7**, e1801496 (2018).
661 <https://doi.org/10.1002/adhm.201801496>
- 662 22 Huang, Y. C., Kaigler, D., Rice, K. G., Krebsbach, P. H. & Mooney, D. J. Combined
663 angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven
664 bone regeneration. *J Bone Miner Res* **20**, 848-857 (2005).
665 <https://doi.org/10.1359/JBMR.041226>
- 666 23 Simmons, C. A., Alsberg, E., Hsiong, S., Kim, W. J. & Mooney, D. J. Dual growth factor
667 delivery and controlled scaffold degradation enhance in vivo bone formation by
668 transplanted bone marrow stromal cells. *Bone* **35**, 562-569 (2004).
669 <https://doi.org/10.1016/j.bone.2004.02.027>
- 670 24 Awale, G. M. *et al.* Regenerative engineering of long bones using the small molecule
671 forskolin. *Proc Natl Acad Sci U S A* **120**, e2219756120 (2023).
672 <https://doi.org/10.1073/pnas.2219756120>
- 673 25 Li, M. *et al.* The genetic background determines material-induced bone formation
674 through the macrophage-osteoclast axis. *Biomaterials* **302**, 122356 (2023).
675 <https://doi.org/10.1016/j.biomaterials.2023.122356>
- 676 26 Shah, N. J. *et al.* An injectable bone marrow-like scaffold enhances T cell immunity after
677 hematopoietic stem cell transplantation. *Nat Biotechnol* **37**, 293-302 (2019).
678 <https://doi.org/10.1038/s41587-019-0017-2>
- 679 27 Boerckel, J. D. *et al.* Effects of protein dose and delivery system on BMP-mediated bone
680 regeneration. *Biomaterials* **32**, 5241-5251 (2011).
681 <https://doi.org/10.1016/j.biomaterials.2011.03.063>
- 682 28 Nakamura, K. *et al.* Sclerostin deficiency effectively promotes bone morphogenetic
683 protein-2-induced ectopic bone formation. *J Periodontal Res* **58**, 769-779 (2023).
684 <https://doi.org/10.1111/jre.13134>
- 685

- 686 29 Wang, X. *et al.* Inhibition of overactive TGF-beta attenuates progression of heterotopic
687 ossification in mice. *Nat Commun* **9**, 551 (2018). [https://doi.org/10.1038/s41467-018-](https://doi.org/10.1038/s41467-018-02988-5)
688 [02988-5](https://doi.org/10.1038/s41467-018-02988-5)
- 689 30 Yang, N. & Liu, Y. The Role of the Immune Microenvironment in Bone Regeneration. *Int*
690 *J Med Sci* **18**, 3697-3707 (2021). <https://doi.org/10.7150/ijms.61080>
- 691 31 Bragdon, B. *et al.* Intrinsic Sex-Linked Variations in Osteogenic and Adipogenic
692 Differentiation Potential of Bone Marrow Multipotent Stromal Cells. *J Cell Physiol* **230**,
693 296-307 (2015). <https://doi.org/10.1002/jcp.24705>
- 694 32 Cui, X. *et al.* Sexual dimorphism in the mouse bone marrow niche regulates
695 hematopoietic engraftment via sex-specific Kdm5c/Cxcl12 signaling. *J Clin Invest* **135**
696 (2025). <https://doi.org/10.1172/JCI182125>
- 697 33 Zanotti, S., Kalajzic, I., Aguila, H. L. & Canalis, E. Sex and genetic factors determine
698 osteoblastic differentiation potential of murine bone marrow stromal cells. *PLoS One* **9**,
699 e86757 (2014). <https://doi.org/10.1371/journal.pone.0086757>
- 700 34 Remark, L. H. *et al.* Loss of Notch signaling in skeletal stem cells enhances bone
701 formation with aging. *Bone Res* **11**, 50 (2023). [https://doi.org/10.1038/s41413-023-](https://doi.org/10.1038/s41413-023-00283-8)
702 [00283-8](https://doi.org/10.1038/s41413-023-00283-8)
- 703 35 Feng, X. Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and
704 Disease. *Curr Chem Biol* **3**, 189-196 (2009).
705 <https://doi.org/10.2174/187231309788166398>
- 706 36 de Guzman, R. C. *et al.* Binding Interactions of Keratin-Based Hair Fiber Extract to
707 Gold, Keratin, and BMP-2. *PLoS One* **10**, e0137233 (2015).
708 <https://doi.org/10.1371/journal.pone.0137233>
- 709 37 Sundermann, J., Zagst, H., Kuntsche, J., Watzig, H. & Bunjes, H. Bone Morphogenetic
710 Protein 2 (BMP-2) Aggregates Can be Solubilized by Albumin-Investigation of BMP-2
711 Aggregation by Light Scattering and Electrophoresis. *Pharmaceutics* **12** (2020).
712 <https://doi.org/10.3390/pharmaceutics12121143>
- 713 38 Aquino-Martinez, R., Artigas, N., Gamez, B., Rosa, J. L. & Ventura, F. Extracellular
714 calcium promotes bone formation from bone marrow mesenchymal stem cells by
715 amplifying the effects of BMP-2 on SMAD signalling. *PLoS One* **12**, e0178158 (2017).
716 <https://doi.org/10.1371/journal.pone.0178158>
- 717 39 Zegzula, H. D., Buck, D. C., Brekke, J., Wozney, J. M. & Hollinger, J. O. Bone formation
718 with use of rhBMP-2 (recombinant human bone morphogenetic protein-2). *J Bone Joint*
719 *Surg Am* **79**, 1778-1790 (1997). <https://doi.org/10.2106/00004623-199712000-00003>
- 720 40 Monsoro-Burq, A. H. *et al.* The role of bone morphogenetic proteins in vertebral
721 development. *Development* **122**, 3607-3616 (1996).
722 <https://doi.org/10.1242/dev.122.11.3607>
- 723 41 Kallai, I. *et al.* Microcomputed tomography-based structural analysis of various bone
724 tissue regeneration models. *Nat Protoc* **6**, 105-110 (2011).
725 <https://doi.org/10.1038/nprot.2010.180>
- 726 42 Kazakia, G. J., Burghardt, A. J., Cheung, S. & Majumdar, S. Assessment of bone tissue
727 mineralization by conventional x-ray microcomputed tomography: comparison with
728 synchrotron radiation microcomputed tomography and ash measurements. *Med Phys* **35**,
729 3170-3179 (2008). <https://doi.org/10.1118/1.2924210>

- 730 43 Burghardt, A. J., Kazakia, G. J., Laib, A. & Majumdar, S. Quantitative assessment of
731 bone tissue mineralization with polychromatic micro-computed tomography. *Calcif*
732 *Tissue Int* **83**, 129-138 (2008). <https://doi.org/10.1007/s00223-008-9158-x>
- 733 44 El Khassawna, T. *et al.* T Lymphocytes Influence the Mineralization Process of Bone.
734 *Front Immunol* **8**, 562 (2017). <https://doi.org/10.3389/fimmu.2017.00562>
- 735 45 Yamaguchi, A. *et al.* Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic
736 differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6.
737 *Biochem Biophys Res Commun* **220**, 366-371 (1996).
738 <https://doi.org/10.1006/bbrc.1996.0411>
- 739 46 Kramann, R. *et al.* Osteogenesis of heterotopically transplanted mesenchymal stromal
740 cells in rat models of chronic kidney disease. *J Bone Miner Res* **28**, 2523-2534 (2013).
741 <https://doi.org/10.1002/jbmr.1994>
- 742 47 Sakurai, T., Sawada, Y., Yoshimoto, M., Kawai, M. & Miyakoshi, J. Radiation-induced
743 reduction of osteoblast differentiation in C2C12 cells. *J Radiat Res* **48**, 515-521 (2007).
744 <https://doi.org/10.1269/jrr.07012>
- 745 48 Dudziak, M. E. *et al.* The effects of ionizing radiation on osteoblast-like cells in vitro.
746 *Plast Reconstr Surg* **106**, 1049-1061 (2000). [https://doi.org/10.1097/00006534-](https://doi.org/10.1097/00006534-200010000-00015)
747 [200010000-00015](https://doi.org/10.1097/00006534-200010000-00015)
- 748 49 Li, J., Kwong, D. L. & Chan, G. C. The effects of various irradiation doses on the growth
749 and differentiation of marrow-derived human mesenchymal stromal cells. *Pediatr*
750 *Transplant* **11**, 379-387 (2007). <https://doi.org/10.1111/j.1399-3046.2006.00663.x>
- 751 50 Cao, X. *et al.* Irradiation induces bone injury by damaging bone marrow
752 microenvironment for stem cells. *Proc Natl Acad Sci U S A* **108**, 1609-1614 (2011).
753 <https://doi.org/10.1073/pnas.1015350108>
- 754 51 Aksu, A. E., Rubin, J. P., Dudas, J. R. & Marra, K. G. Role of gender and anatomical
755 region on induction of osteogenic differentiation of human adipose-derived stem cells.
756 *Ann Plast Surg* **60**, 306-322 (2008). <https://doi.org/10.1097/SAP.0b013e3180621ff0>
- 757 52 Corsi, K. A. *et al.* Osteogenic potential of postnatal skeletal muscle-derived stem cells is
758 influenced by donor sex. *J Bone Miner Res* **22**, 1592-1602 (2007).
759 <https://doi.org/10.1359/jbmr.070702>
- 760 53 Mun, S. H. *et al.* Sexual Dimorphism in Differentiating Osteoclast Precursors
761 Demonstrates Enhanced Inflammatory Pathway Activation in Female Cells. *J Bone*
762 *Miner Res* **36**, 1104-1116 (2021). <https://doi.org/10.1002/jbmr.4270>
- 763 54 Strube, P. *et al.* Sex-specific compromised bone healing in female rats might be
764 associated with a decrease in mesenchymal stem cell quantity. *Bone* **45**, 1065-1072
765 (2009). <https://doi.org/10.1016/j.bone.2009.08.005>
- 766 55 Shepherd, R., Cheung, A. S., Pang, K., Saffery, R. & Novakovic, B. Sexual Dimorphism
767 in Innate Immunity: The Role of Sex Hormones and Epigenetics. *Front Immunol* **11**,
768 604000 (2020). <https://doi.org/10.3389/fimmu.2020.604000>
- 769 56 Jaillon, S., Berthenet, K. & Garlanda, C. Sexual Dimorphism in Innate Immunity. *Clin*
770 *Rev Allergy Immunol* **56**, 308-321 (2019). <https://doi.org/10.1007/s12016-017-8648-x>
- 771 57 Casimir, G. J., Lefevre, N., Corazza, F. & Duchateau, J. Sex and inflammation in
772 respiratory diseases: a clinical viewpoint. *Biol Sex Differ* **4**, 16 (2013).
773 <https://doi.org/10.1186/2042-6410-4-16>

774 58 Adu-Berchie, K. *et al.* Adoptive T cell transfer and host antigen-presenting cell
775 recruitment with cryogel scaffolds promotes long-term protection against solid tumors.
776 *Nat Commun* **14**, 3546 (2023). <https://doi.org/10.1038/s41467-023-39330-7>

777

778 **Acknowledgements**

779 The authors thank Milton Cornwall-Brady for assistance with microCT analysis, Roderick
780 Bronson, pathologist, for assistance with histology analysis, Dr. Alex Najibi for assistance with
781 ultrasonography imaging and Dr. Ting-Yu Shih for support with polymer synthesis. Histology
782 imaging, consultation and services were performed in the Dana-Farber/Harvard Cancer Center in
783 the Harvard Medical School. The authors also thank the staff at the Wyss Institute for Biologically
784 Inspired Engineering at Harvard University for providing the support needed to perform the
785 required experiments. This work was supported by the Lightning Biotherapeutics.

786

787 **Author contributions**

788 S.L., K.A.-B., and A.S.S. conceptualized and designed the study. S.L., K.A.-B., A.S.S., T.T., N.D.,
789 A.S., K.S., C.J., H.I., P.K., M.C., S.E., M.C.S. were conducted experiments. S.L., K.A.-B., and
790 A.S.S. analyzed data. S.L., K.A.-B., A.S.S., D.T.S., and D.J.M. wrote and edited the manuscript.
791 All authors have read and contributed to editing the manuscript.

792

793 **Competing interests**

794 D.J.M. declares the following competing interests: Novartis, sponsored research, licensed IP;
795 Immulus, equity; IVIVA, SAB; Attivare, SAB, equity; Lyell, licensed IP, equity. D.T.S. declares
796 the following competing interests: Clear Creek Bio, VCanBio, Garuda Therapeutics, Editas

797 Medicine, Sonata Therapeutics, Carisma Therapeutics, Agios Pharmaceuticals. All the other
798 authors declare no competing interests.